ProfileGDS5678 / 1447951_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 65% 65% 65% 65% 62% 68% 69% 68% 66% 65% 67% 62% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7099861
GSM967853U87-EV human glioblastoma xenograft - Control 23.8675565
GSM967854U87-EV human glioblastoma xenograft - Control 33.9214865
GSM967855U87-EV human glioblastoma xenograft - Control 43.8968265
GSM967856U87-EV human glioblastoma xenograft - Control 53.9077565
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7692262
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2043868
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2877769
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.129668
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0101266
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8910365
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1113367
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7480562
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8954465